Business Description
Spyre Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00773J1034
Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.78 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.7 | |||||
| 3-Year FCF Growth Rate | 28.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.57 | |||||
| 9-Day RSI | 38.56 | |||||
| 14-Day RSI | 40.55 | |||||
| 6-1 Month Momentum % | 5.43 | |||||
| 12-1 Month Momentum % | 115.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.32 | |||||
| Quick Ratio | 7.32 | |||||
| Cash Ratio | 7.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -165.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -17070.77 | |||||
| ROE % | -135.56 | |||||
| ROA % | -56.74 | |||||
| ROIC % | -1619.64 | |||||
| ROC (Joel Greenblatt) % | -8422.58 | |||||
| ROCE % | -57.56 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 234.96 | |||||
| PB Ratio | 8.52 | |||||
| Price-to-Tangible-Book | 8.51 | |||||
| EV-to-EBIT | -7.76 | |||||
| EV-to-EBITDA | -7.76 | |||||
| EV-to-Revenue | 1709.56 | |||||
| EV-to-Forward-Revenue | 18.54 | |||||
| EV-to-FCF | -10.01 | |||||
| Price-to-Net-Current-Asset-Value | 8.51 | |||||
| Price-to-Net-Cash | 4.56 | |||||
| Earnings Yield (Greenblatt) % | -12.89 | |||||
| FCF Yield % | -9.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SYRE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spyre Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.886 | ||
| EPS (TTM) ($) | -4.122 | ||
| Beta | 4.01 | ||
| Volatility % | 63.41 | ||
| 14-Day RSI | 40.55 | ||
| 14-Day ATR ($) | 1.98134 | ||
| 20-Day SMA ($) | 31.89925 | ||
| 12-1 Month Momentum % | 115.01 | ||
| 52-Week Range ($) | 14.22 - 47.97 | ||
| Shares Outstanding (Mil) | 58.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spyre Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spyre Therapeutics Inc Frequently Asked Questions
What is Spyre Therapeutics Inc(SYRE)'s stock price today?
The current price of SYRE is $28.43. The 52 week high of SYRE is $47.97 and 52 week low is $14.22.
When is next earnings date of Spyre Therapeutics Inc(SYRE)?
The next earnings date of Spyre Therapeutics Inc(SYRE) is 2025-02-28 Est..
Does Spyre Therapeutics Inc(SYRE) pay dividends? If so, how much?
Spyre Therapeutics Inc(SYRE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers